Evidence map›Paper›PMID 40830509›Full record

ReviewMolecular biomedicine2025

Mucosal immunity and vaccination strategies: current insights and future perspectives.

Zhihao Zhang, Weiqi Hong, Yu Zhang, Xin Li, Haiying Que, Xiawei Wei

Abstract readReview
In one paragraph

Review in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhihao Zhang *State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Weiqi Hong *State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yu ZhangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xin LiState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Haiying QueState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xiawei WeiState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. xiaweiwei@scu.edu.cn.ORCID http://orcid.org/0000-0002-6513-6422

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mucosal immune system represents a critical defense mechanism, safeguarding the body from an array of external pathogens. As the body's first line of immune protection, it plays an essential role in initiating both innate and adaptive immune responses. Through intricate networks of immune cells and complex molecular pathways, mucosal immunity orchestrates a robust defense not only at the local level but also activates systemic immune responses to ensure comprehensive protection. Consequently, the mucosal immune system has garnered immense interest in the field of vaccine development, given its potential to foster durable and effective immunization. Despite the profound promise of mucosal immunity, the development of mucosal vaccines faces significant challenges, particularly with existing technological platforms that primarily rely on live attenuated or inactivated vaccines. However, emerging innovative platforms, including subunit vaccines, viral vector vaccines, and the groundbreaking application of mRNA vaccines, are offering new perspectives, vastly improving the scope and efficacy of mucosal immunization. As mucosal immunity research continues to evolve, rapid advancements in biotechnology and immunology provide promising strategies to enhance immune responses and overcome inherent limitations. This review delves into the latest progress in oral, nasal, and other forms of mucosal vaccines, analyzing the intricate relationship between mucosal immune characteristics and vaccine design. Emphasis is placed on the pivotal role of advanced adjuvants and delivery systems in maximizing vaccine efficacy. This review addresses current challenges, highlights future research opportunities, and aims to provide a comprehensive framework for advancing the field of mucosal immunity and vaccine development.

Indexed as

Immunity, MucosalVaccinationVaccinesAdjuvants, ImmunologicAnimalsHumansVaccine DevelopmentAdjuvants, ImmunologicVaccinesAdjuvantsMucosal immunityMucosal technology platformVaccine deliveryVaccine development

Identifiers

PMID40830509
PMCPMC12364801

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.